Work

Phase II double-blind, randomized study of selumetinib (SEL) plus docetaxel (DOC) versus DOC plus placebo as second-line treatment for advanced KRAS mutant non-small cell lung cancer (NSCLC).

Year: 2012

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2012.30.15_suppl.7503

Authors: Pasi A. Janne, Alice Tsang Shaw, Jose Rodrigues Pereira, Gaelle Jeannin, Johan Vansteenkiste, Carlos H. Barrios, Fabio A. Franke, Lynda Grinsted, Paul D. Smith, Victoria Zazulina, Ian C. Smith, Lucio Crino

Institutions: Dana-Farber Cancer Institute, Massachusetts General Hospital, Centre Hospitalier Universitaire de Clermont-Ferrand, Universitair Ziekenhuis Leuven, KU Leuven, Pontifícia Universidade Católica do Rio Grande do Sul, Hospital São José do Avaí, Hospital Araújo Jorge, Instituto Ivoti, Ichinomiyanishi Hospital, AstraZeneca (United Kingdom), University of Perugia

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W1789083511

Cites:

Cited by: 36

Related to: 10